Howdy folks. How was your Thursday? It wasn't a particularly great one for the market. Yeah, the 0.14% dip from the S&P 500 wasn't huge, but in some regards could still be considered a troubling blow. With the small move lower, the index is now below a key line in the sand. We'll talk about it below, in a moment. The first thing we want to do today is make sure you saw yesterday's news from Vitality Biopharma (VBIO). Long story made short, Vitality Biopharma just beefed up its intellectual property portfolio by fling a couple of new patents. Just as a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic ("getting high') effects, and without some of the common downsides associated with these pharmaceuticals... like mouth and skin lesions. It can make prodrugs of some of the more compelling cannabinoid drugs, which just means it doesn't become its active form until it reaches its destination in the body. In any case, what was already a rather robust IP portfolio -- the company's got 40 pending patents on cannabinoid-based glycoside prodrugs -- got a little beefier today with the submission two more patent applications. For those of you who are into the science of cannabinoids, the company's press release is right here, which serves up some of the relevant details. If instead you just want the simplified explanation of what VBIO just requested a patent on, I recommend Matthew Briar's explanation posted at the website today. I'll even give you a teaser... the same pain sensor that tends to be more common in those people inflammatory bowel disease is readily blocked by one of the cannabinoid drugs Vitality Biopharma is developing. With 40 patents on the table though, VBIO could end up with several profit centers. I think it's interesting, and telling, that Vitality Biopharma is starting to talk about some of the specifics of its pipeline. Sometimes you have to look beyond the headlines themselves and think about the timing and the "why?" of a company's news releases. On other fronts, how about MagicJack Vocaltec (CALL)... the freebie trade we suggested last Friday? Assuming you got in at the opening price of $5.85 this Monday, you're now up about 10% on the trade. I don't bring MagicJack up to pat ourselves on the back though. I'm talking about it again today because I want to take a close look at the chart - there's a lot to be learned here, and a lot to be encouraged by. Take a look. This is an ideal setup. The sharp V-shaped reversal from last week was decisive, and got off to a great start.... too good in some ways. That's where Wednesday's pause came from, and that's why things got a little alarming earlier today. All it took was a brush of the 20-day moving average line (blue) at $5.94, however, to rekindle the uptrend that got started last week. That's as it should be. When a stock verifies support at key lines, it's a good thing. The other benefit of Wednesday's and early-Thursday's low was that it sloughed off any weak hands and would-be profit takers. The clincher here is the volume All the up days have been on high volume, and the one bearish day -- Wednesday -- in all this was on low volume. This is a big hint that the bullishness represents the majority opinion right now. There are two reasons we're making a point of taking this focused look. One is just to confirm the strength of this trade. If you wanted to make a play on CALL but hadn't yet, the risk/reward is still favorable for an entry. The second (and more important) reason is, these are all subtle clues you'll often see when a stock is trying to firm up a new uptrend. When you see things like a brush of, and then reversal from, a moving average line at the same time you see this kind of lopsided volume, the budding rally effort may be healthier than you think. Last but not least, I want to show you our usual chart of the S&P 500 through today, but only for the purpose of comparing it to the other chart I'm going to show you, which comes to us courtesy of the Elite Opportunity Pro newsletter. Here's ours. Note the close below 2176. And, here's the one from the EO Pro. What you're not seeing is the extensive commentary John Monroe also served up with that detailed technical analysis chart. (Sorry, but we can't give everything away.) Even with just the image, however, you can glean a lot about what's really going on with the market now. Sometimes things are what they seem. Sometimes they aren't. Sometimes you have to look at a LOT of information to come to any clear conclusion, or recognize that there is no clear conclusion yet. The moral of the story is, while it's easy even for the most experienced of traders to hone their attention on just the tools -- or just one tool -- that agrees with the opinion they've already formed, looking at everything forces a trader to accept what he or she may not have chosen to believe. Although the Elite Opportunity Pro team doesn't talk about such a detailed chart every day, nor show such a detailed chart to its readers, John and his crew do look at the above chart every single day, just to make sure they're seeing things clearly and aren't looking at the market with a bias. I'm pretty convinced this is one of the biggest reasons the Elite Opportunity Pro is usually right about what's in store for the market (and why EO Pro members are doing so well with their index-based trades). Here's how you can access that insight.